AUL
RARE icon

AlphaGrep UK Ltd’s Ultragenyx Pharmaceutical RARE Stock Holding History

AlphaGrep UK Ltd’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$362K Buy
+17,299
New +$390K 0.1% 423

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

AlphaGrep UK Ltd's RARE Position: Q1 2026 in Review

AlphaGrep UK Ltd opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 17,299 shares worth $362K. The stake represents 0.1% of the portfolio and ranks #423 among its holdings.

297 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • AlphaGrep UK Ltd held 17,299 shares of Ultragenyx Pharmaceutical worth $362K as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new AlphaGrep UK Ltd position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.1% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #423 holding.
  • 297 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.